Discovery of potent and selective p53-MDM2 protein–protein interaction inhibitors as anticancer drugs

Abstract

As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs.